198 related articles for article (PubMed ID: 19896233)
41. A comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naive patients with type 2 diabetes.
Borah BJ; Darkow T; Bouchard J; Aagren M; Forma F; Alemayehu B
Clin Ther; 2009 Mar; 31(3):623-31. PubMed ID: 19393853
[TBL] [Abstract][Full Text] [Related]
42. A comparison of costs among patients with type 2 diabetes mellitus who initiated therapy with exenatide or insulin glargine.
Misurski D; Lage MJ; Fabunmi R; Boye KS
Appl Health Econ Health Policy; 2009; 7(4):245-54. PubMed ID: 19905038
[TBL] [Abstract][Full Text] [Related]
43. [BOT with insulin glargine versus BOT with insulin detemir: comparison of treatment costs in type 2 diabetes based on the results of the insulin glargine (Lantus) versus insulin detemir (Levemir) Treat-To-Target (L2T3) study from the German Statutory Health Insurance perspective].
Schädlich PK; Koltermann KC; Dippel FW; Hagenmeyer EG; Häussler B
MMW Fortschr Med; 2010 Oct; 152 Suppl 3():89-95. PubMed ID: 21595152
[No Abstract] [Full Text] [Related]
44. Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German setting.
Mittendorf T; Smith-Palmer J; Timlin L; Happich M; Goodall G
Diabetes Obes Metab; 2009 Nov; 11(11):1068-79. PubMed ID: 19732121
[TBL] [Abstract][Full Text] [Related]
45. Hypoglycemic events and glycosylated hemoglobin values in patients with type 2 diabetes mellitus newly initiated on insulin glargine or premixed insulin combination products.
Bullano MF; Fisher MD; Grochulski WD; Menditto L; Willey VJ
Am J Health Syst Pharm; 2006 Dec; 63(24):2473-82. PubMed ID: 17158695
[TBL] [Abstract][Full Text] [Related]
46. Comparison of daily insulin dose and other antidiabetic medications usage for type 2 diabetes patients treated with an analog basal insulin.
McAdam-Marx C; Yu J; Bouchard J; Aagren M; Brixner DI
Curr Med Res Opin; 2010 Jan; 26(1):191-201. PubMed ID: 19919375
[TBL] [Abstract][Full Text] [Related]
47. Direct medical costs for complications among children and adults with diabetes in the US commercial payer setting.
Yeaw J; Halinan S; Hines D; Delozier A; Perez M; Boye M; Boye KS; Blanchette CM
Appl Health Econ Health Policy; 2014 Apr; 12(2):219-30. PubMed ID: 24573912
[TBL] [Abstract][Full Text] [Related]
48. Assessment of adherence and healthcare costs of insulin device (FlexPen) versus conventional vial/syringe.
Baser O; Bouchard J; DeLuzio T; Henk H; Aagren M
Adv Ther; 2010 Feb; 27(2):94-104. PubMed ID: 20352392
[TBL] [Abstract][Full Text] [Related]
49. Evaluation of the long-term cost-effectiveness of insulin detemir compared with neutral protamine hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in Sweden.
Valentine WJ; Aagren M; Haglund M; Ericsson A; Gschwend MH
Scand J Public Health; 2011 Feb; 39(1):79-87. PubMed ID: 20688795
[TBL] [Abstract][Full Text] [Related]
50. Incremental cost savings 6 months following initiation of insulin glargine in a Medicaid fee-for-service sample.
Zhang Q; Menditto L
Am J Ther; 2005; 12(4):337-43. PubMed ID: 16041197
[TBL] [Abstract][Full Text] [Related]
51. Adherence and persistence to a regimen of basal insulin in a pre-filled pen compared to vial/syringe in insulin-naïve patients with type 2 diabetes.
Buysman E; Conner C; Aagren M; Bouchard J; Liu F
Curr Med Res Opin; 2011 Sep; 27(9):1709-17. PubMed ID: 21740289
[TBL] [Abstract][Full Text] [Related]
52. Hypoglycemia After Initiation of Basal Insulin in Patients with Type 2 Diabetes in the United States: Implications for Treatment Discontinuation and Healthcare Costs and Utilization.
Dalal MR; Kazemi M; Ye F; Xie L
Adv Ther; 2017 Sep; 34(9):2083-2092. PubMed ID: 28779282
[TBL] [Abstract][Full Text] [Related]
53. Utilization and costs for compliant patients initiating therapy with pioglitazone or rosiglitazone versus insulin in a Medicaid fee-for-service population.
Kalsekar I; Iyer S; Mody R; Rajagopalan R; Kavookjian J
J Manag Care Pharm; 2006 Mar; 12(2):121-9. PubMed ID: 16515370
[TBL] [Abstract][Full Text] [Related]
54. The incidence and costs of hypoglycemia in type 2 diabetes.
Quilliam BJ; Simeone JC; Ozbay AB; Kogut SJ
Am J Manag Care; 2011 Oct; 17(10):673-80. PubMed ID: 22106460
[TBL] [Abstract][Full Text] [Related]
55. Medical resource use, disturbance of daily life and burden of hypoglycemia in insulin-treated patients with diabetes: results from a European online survey.
Willis WD; Diago-Cabezudo JI; Madec-Hily A; Aslam A
Expert Rev Pharmacoecon Outcomes Res; 2013 Feb; 13(1):123-30. PubMed ID: 23402452
[TBL] [Abstract][Full Text] [Related]
56. The association between use of mealtime insulin pens versus vials and healthcare charges and resource utilization in patients with type 2 diabetes: a retrospective cohort study.
Eby EL; Boye KS; Lage MJ
J Med Econ; 2013 Oct; 16(10):1231-7. PubMed ID: 23834480
[TBL] [Abstract][Full Text] [Related]
57. Comparison of utilization, cost, adherence, and hypoglycemia in patients with type 2 diabetes initiating rapid-acting insulin analog with prefilled pen versus vial/syringe.
Lee LJ; Li Q; Reynolds MW; Pawaskar MD; Corrigan SM
J Med Econ; 2011; 14(1):75-86. PubMed ID: 21231863
[TBL] [Abstract][Full Text] [Related]
58. The association of insulin medication possession ratio, use of insulin glargine, and health benefit costs in employees and spouses with type 2 diabetes.
Kleinman NL; Schaneman JL; Lynch WD
J Occup Environ Med; 2008 Dec; 50(12):1386-93. PubMed ID: 19092494
[TBL] [Abstract][Full Text] [Related]
59. Real-world comparative outcomes of US type 2 diabetes patients initiating analog basal insulin therapy.
Davis KL; Tangirala M; Meyers JL; Wei W
Curr Med Res Opin; 2013 Sep; 29(9):1083-91. PubMed ID: 23734906
[TBL] [Abstract][Full Text] [Related]
60. Economic impact of hypoglycemia on healthcare in Spain.
Brito-Sanfiel M; Diago-Cabezudo J; Calderon A
Expert Rev Pharmacoecon Outcomes Res; 2010 Dec; 10(6):649-60. PubMed ID: 21155698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
